首页> 美国卫生研究院文献>Oncotarget >Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging
【2h】

Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging

机译:用于转移性前列腺癌识别和组织成像的DNA适体的选择和表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prostate cancer (PCa) is the second leading cause of death and most prevalent cancer in men. The absence of curative options for castration-resistant metastatic prostate cancer and biomarkers able to discriminate between indolent and aggressive tumors contribute to these statistics. In this study, a DNA aptamer termed DML-7 was successfully selected against human PCa cell line DU145 by using the cell-based systematic evolution of ligands by exponential enrichment (SELEX) method. The selected aptamer DML-7 was found to internalize into target cells in a temperature-dependent manner and exhibit high binding affinity for target cells with dissociation constants in the nanomolar range. Binding analysis further revealed that DML-7 only binds to DU145 and PC-3 cells with metastatic potential, but not to LNCaP or 22Rv1 cells with low or nonmetastatic potential, demonstrating that DML-7 has excellent selectivity for the recognition of the metastatic PCa cells. Clinical tissue imaging further confirmed these results. Therefore, both high binding affinity and specificity to metastatic PCa cells and tissues afford DML-7 with the potential for development into a novel tool for diagnosis and targeted drug delivery against metastatic prostate cancer.
机译:前列腺癌(PCa)是男性的第二大死亡原因和最普遍的癌症。缺乏去势抵抗性转移性前列腺癌的治疗选择以及能够区分惰性肿瘤和侵袭性肿瘤的生物标记物有助于这些统计数据。在这项研究中,通过使用基于细胞的指数富集(SELEX)方法系统进化的配体,成功地针对人PCa细胞株DU145选择了一种称为DML-7的DNA适体。发现选择的适体DML-7以温度依赖性方式内在化进入靶细胞,并以解离常数在纳摩尔范围内对靶细胞表现出高结合亲和力。结合分析进一步表明,DML-7仅与具有转移潜能的DU145和PC-3细胞结合,而与具有低转移或非转移潜能的LNCaP或22Rv1细胞结合,表明DML-7对转移PCa细胞的识别具有极好的选择性。临床组织成像进一步证实了这些结果。因此,对转移性PCa细胞和组织的高结合亲和力和特异性都为DML-7提供了开发成针对转移性前列腺癌的诊断和靶向药物递送的新工具的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号